<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00279955</url>
  </required_header>
  <id_info>
    <org_study_id>235</org_study_id>
    <nct_id>NCT00279955</nct_id>
  </id_info>
  <brief_title>PARTNERS HF: Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure</brief_title>
  <official_title>Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the value of diagnostic data obtained from
      Medtronic implantable cardioverter defibrillators (ICDs) with cardiac resynchronization
      therapy (CRT) to evaluate cardiovascular and heart failure related adverse events and health
      care utilization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Heart Failure (HF) Related Adverse Event (AE)</measure>
    <time_frame>From 6 month to the 12 month visit</time_frame>
    <description>Number of participates with HF realted adverse event will be reported. Time to the first HF related Adverse event in the &quot;Follow-up Period&quot; from the 6-month visit to the 12-month visit is compared between two risk groups. The goal was to test if there is a significant difference in time to first HF-related adverse event between two groups. A heart failure related (HF-related) adverse event is defined as an adverse event that results in a subject's worsening HF or related to the heart's inability to meet the metabolic demands of the body.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Heart Failure (HF) Related Healthcare Utilization (HU)</measure>
    <time_frame>6 month to the 12 month visit</time_frame>
    <description>Number of participates with HF realted healthcare utilization will be reported. Time to the first HF-related healthcare utilization in the &quot;Follow-up Period&quot; from the 6-month visit to the 12-month visit is compared between two risk groups. The goal was to test if there is a significant difference in time to first HF-related healthcare utilization between two groups. A heart failure related (HF-related) healthcare utilization is defined as unscheduled office visits, hospitalizations, urgent care visits, and emergency room visits which is resulted by heart failure related adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Heart Failure (HF) Related Pulmonary Congestion Event (PCE)</measure>
    <time_frame>6 month to the 12 month visit</time_frame>
    <description>Number of participates with HF related pulmonary congestion event will be reported. Time to the first HF related pulmonary cogestion event in the &quot;Follow-up Period&quot; from the 6-month visit to the 12-month visit is compared between two risk groups to see if there is significant difference. A HF related pulmonary congestion event is defined as hospitalization with signs and/or symptoms of pulmonary congestion, or outpatient treatment with IV diuretics due to exacerbation of HF with signs and/or symptoms of pulmonary congestion.</description>
  </secondary_outcome>
  <enrollment type="Actual">1024</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac Resynchronization Therapy Device</intervention_name>
    <description>Patients with an ICD indication, a CRT indication and symptomatic heart failure who are implanted with a Cardiac Resynchronization Therapy Device.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving a specified Medtronic Implantable Cardiac Resynchronization Therapy
        Defibrillator device where informed consent and/or authorization to use and disclose health
        information permission has been granted.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who meet the ICD indications

          -  Patients with Class III or IV heart failure.

          -  Patients receiving or who received a Medtronic CRT ICD within the previous 3 months.

          -  Patient must sign and date informed consent, and be 18 years of age or greater.

          -  Patient must be available for follow up visits, and be willing and able to comply with
             study protocol.

        Exclusion Criteria:

          -  Patient with acute myocardial infarction (MI), coronary artery bypass graft surgery
             (CABG) or percutaneous coronary angioplasty (PTCA)/stent within the last month.

          -  Patient with a mechanical right heart valve.

          -  Patient with chronic (permanent) atrial arrhythmias.

          -  Patient with life expectancy of less than 12 months.

          -  Patient with status post heart transplant

          -  Patient undergoing kidney dialysis

          -  Patients enrolled in a concurrent study that may confound the results of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Whellan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jefferson Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guilford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Key Largo</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Safety Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merrionette Park</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florence</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marquette</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Cloud</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cherryhill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sewell</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Islip</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Lake</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wormleysburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pawtucket</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2006</study_first_submitted>
  <study_first_submitted_qc>January 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2006</study_first_posted>
  <results_first_submitted>July 20, 2011</results_first_submitted>
  <results_first_submitted_qc>November 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 8, 2011</results_first_posted>
  <last_update_submitted>June 11, 2012</last_update_submitted>
  <last_update_submitted_qc>June 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure, Congestive</keyword>
  <keyword>Implantable Cardioverter-Defibrillators</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1024 subjects were enrolled in the study from 21 JUN 2004 through 14 FEB 2007 from 100 centers in US. Follow-up data collection ended on 06 MAR 2008.</recruitment_details>
      <pre_assignment_details>23 of 1024 subjects exited prior to successful implant due to not meeting in/exclusion criteria, unsucessful implants, missing informed consent form etc. Of the remaining 1001 subjects, 643 subjects had been followed longer than 6 months and had the OptiVol feature save-to-disk data available. Those 643 subjects were used for analyzing objectives.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>At Least 1 OptiVol Fluid Index &gt; 100 During DREP</title>
          <description>All subjects who were followed longer than 6 months and had OptiVol fluid index crossing 100 during DREP. An OptiVol index &gt; 100 indicates potential fluid retention in the lungs. DREP: Diagnostic Risk Evaluation Period which is defined from consent date or implant date to 6 month visit.</description>
        </group>
        <group group_id="P2">
          <title>No OptiVol Fluid Index &gt; 100 During DREP</title>
          <description>All subjects who were followed longer than 6 months and never had OptiVol Fliud index crossing 100 during DREP. DREP: Diagnostic Risk Evaluation Period which is defined from consent date or implant date to 6 month visit.</description>
        </group>
        <group group_id="P3">
          <title>No OptiVol Measurement</title>
          <description>All subjects either who were not followed for at least 6 months, or didn't have OptiVol Fluid Index measurements available.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="486"/>
                <participants group_id="P3" count="358"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="486"/>
                <participants group_id="P3" count="358">They are still counted as completes, though they are never used for the analyses of objectives.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>At Least 1 OptiVol Fluid Index &gt; 100 During DREP</title>
          <description>All subjects who were followed longer than 6 months and had OptiVol fluid index crossing 100 during DREP. An OptiVol index &gt; 100 indicates potential fluid retention in the lungs. DREP: Diagnostic Risk Evaluation Period which is defined from consent date or implant date to 6 month visit.</description>
        </group>
        <group group_id="B2">
          <title>No OptiVol Fluid Index &gt; 100 During DREP</title>
          <description>All subjects who were followed longer than 6 months and never had OptiVol Fliud index crossing 100 during DREP. DREP: Diagnostic Risk Evaluation Period which is defined from consent date or implant date to 6 month visit.</description>
        </group>
        <group group_id="B3">
          <title>No OptiVol Measurement</title>
          <description>All subjects either who were not followed for at least 6 months, or didn't have OptiVol Fluid Index measurements available.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="157"/>
            <count group_id="B2" value="486"/>
            <count group_id="B3" value="358"/>
            <count group_id="B4" value="1001"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.8" spread="11.0"/>
                    <measurement group_id="B2" value="68.2" spread="10.6"/>
                    <measurement group_id="B3" value="68.5" spread="11.0"/>
                    <measurement group_id="B4" value="68.4" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="323"/>
                    <measurement group_id="B3" value="249"/>
                    <measurement group_id="B4" value="684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="486"/>
                    <measurement group_id="B3" value="358"/>
                    <measurement group_id="B4" value="1001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Heart Failure (HF) Related Adverse Event (AE)</title>
        <description>Number of participates with HF realted adverse event will be reported. Time to the first HF related Adverse event in the “Follow-up Period” from the 6-month visit to the 12-month visit is compared between two risk groups. The goal was to test if there is a significant difference in time to first HF-related adverse event between two groups. A heart failure related (HF-related) adverse event is defined as an adverse event that results in a subject’s worsening HF or related to the heart’s inability to meet the metabolic demands of the body.</description>
        <time_frame>From 6 month to the 12 month visit</time_frame>
        <population>Of the 1001 subjects meeting inclusion and exclusion criteria, 643 subjects had been followed longer than 6 months and had the OptiVolTM feature save-to-disk data available. Those 643 subjects were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>At Least 1 OptiVol Fluid Index &gt; 100 During DREP</title>
            <description>All subjects who were followed longer than 6 months and had OptiVol fluid index crossing 100 during DREP. An OptiVol index &gt; 100 indicates potential fluid retention in the lungs. DREP: Diagnostic Risk Evaluation Period which is defined from consent date or implant date to 6 month visit.</description>
          </group>
          <group group_id="O2">
            <title>No OptiVol Fluid Index &gt; 100 During DREP</title>
            <description>All subjects who were followed longer than 6 months and never had OptiVol Fliud index crossing 100 during DREP. DREP: Diagnostic Risk Evaluation Period which is defined from consent date or implant date to 6 month visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Heart Failure (HF) Related Adverse Event (AE)</title>
          <description>Number of participates with HF realted adverse event will be reported. Time to the first HF related Adverse event in the “Follow-up Period” from the 6-month visit to the 12-month visit is compared between two risk groups. The goal was to test if there is a significant difference in time to first HF-related adverse event between two groups. A heart failure related (HF-related) adverse event is defined as an adverse event that results in a subject’s worsening HF or related to the heart’s inability to meet the metabolic demands of the body.</description>
          <population>Of the 1001 subjects meeting inclusion and exclusion criteria, 643 subjects had been followed longer than 6 months and had the OptiVolTM feature save-to-disk data available. Those 643 subjects were included in this analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0119</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>2.07</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.292</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>3.67</ci_upper_limit>
            <estimate_desc>The estimated parameter in a Cox regression model was adjusted by age, gender, New York Heart Association (NYHA) class at 6 month visit, Angiotensin Converting Enzyme (ACE)/Angiotensin Receptor Blocker (ARB) at 6 months, and Diuretics at 6 month.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Heart Failure (HF) Related Healthcare Utilization (HU)</title>
        <description>Number of participates with HF realted healthcare utilization will be reported. Time to the first HF-related healthcare utilization in the “Follow-up Period” from the 6-month visit to the 12-month visit is compared between two risk groups. The goal was to test if there is a significant difference in time to first HF-related healthcare utilization between two groups. A heart failure related (HF-related) healthcare utilization is defined as unscheduled office visits, hospitalizations, urgent care visits, and emergency room visits which is resulted by heart failure related adverse event.</description>
        <time_frame>6 month to the 12 month visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>At Least 1 OptiVol Fluid Index &gt; 100 During DREP</title>
            <description>All subjects who were followed longer than 6 months and had OptiVol fluid index crossing 100 during DREP. An OptiVol index &gt; 100 indicates potential fluid retention in the lungs. DREP: Diagnostic Risk Evaluation Period which is defined from consent date or implant date to 6 month visit.</description>
          </group>
          <group group_id="O2">
            <title>No OptiVol Fluid Index &gt; 100 During DREP</title>
            <description>All subjects who were followed longer than 6 months and never had OptiVol Fliud index crossing 100 during DREP. DREP: Diagnostic Risk Evaluation Period which is defined from consent date or implant date to 6 month visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Heart Failure (HF) Related Healthcare Utilization (HU)</title>
          <description>Number of participates with HF realted healthcare utilization will be reported. Time to the first HF-related healthcare utilization in the “Follow-up Period” from the 6-month visit to the 12-month visit is compared between two risk groups. The goal was to test if there is a significant difference in time to first HF-related healthcare utilization between two groups. A heart failure related (HF-related) healthcare utilization is defined as unscheduled office visits, hospitalizations, urgent care visits, and emergency room visits which is resulted by heart failure related adverse event.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0185</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.90</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.277</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>3.27</ci_upper_limit>
            <estimate_desc>The estimated parameter in a Cox regression model was adjusted by age, gender, NYHA class at 6 month visit, ACE/ARB at 6 months, and and at least one day where CRT pacing &lt;90% in last 21 days of DREP.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Heart Failure (HF) Related Pulmonary Congestion Event (PCE)</title>
        <description>Number of participates with HF related pulmonary congestion event will be reported. Time to the first HF related pulmonary cogestion event in the “Follow-up Period” from the 6-month visit to the 12-month visit is compared between two risk groups to see if there is significant difference. A HF related pulmonary congestion event is defined as hospitalization with signs and/or symptoms of pulmonary congestion, or outpatient treatment with IV diuretics due to exacerbation of HF with signs and/or symptoms of pulmonary congestion.</description>
        <time_frame>6 month to the 12 month visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>At Least 1 OptiVol Fluid Index &gt; 100 During DREP</title>
            <description>All subjects who were followed longer than 6 months and had OptiVol fluid index crossing 100 during DREP. An OptiVol index &gt; 100 indicates potential fluid retention in the lungs. DREP: Diagnostic Risk Evaluation Period which is defined from consent date or implant date to 6 month visit.</description>
          </group>
          <group group_id="O2">
            <title>No OptiVol Fluid Index &gt; 100 During DREP</title>
            <description>All subjects who were followed longer than 6 months and never had OptiVol Fliud index crossing 100 during DREP. DREP: Diagnostic Risk Evaluation Period which is defined from consent date or implant date to 6 month visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Heart Failure (HF) Related Pulmonary Congestion Event (PCE)</title>
          <description>Number of participates with HF related pulmonary congestion event will be reported. Time to the first HF related pulmonary cogestion event in the “Follow-up Period” from the 6-month visit to the 12-month visit is compared between two risk groups to see if there is significant difference. A HF related pulmonary congestion event is defined as hospitalization with signs and/or symptoms of pulmonary congestion, or outpatient treatment with IV diuretics due to exacerbation of HF with signs and/or symptoms of pulmonary congestion.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0578</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.80</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.311</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>3.31</ci_upper_limit>
            <estimate_desc>A Cox regression model has been used here, and the estimated parameter has been adjusted by including covariates age, gender, and NYHA class at 6 months.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Those adverse events were collected during the study (0 to 12 month follow-up).</time_frame>
      <desc>All adverse events which resulted in hospitalization are listed as serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>At Least 1 OptiVol Fluid Index &gt; 100 During DREP</title>
          <description>All subjects who were followed longer than 6 months and had OptiVol fluid index crossing 100 during DREP. An OptiVol index &gt; 100 indicates potential fluid retention in the lungs. DREP: Diagnostic Risk Evaluation Period which is defined from consent date or implant date to 6 month visit.</description>
        </group>
        <group group_id="E2">
          <title>No OptiVol Fluid Index &gt; 100 During DREP</title>
          <description>All subjects who were followed longer than 6 months and never had OptiVol Fliud index crossing 100 during DREP. DREP: Diagnostic Risk Evaluation Period which is defined from consent date or implant date to 6 month visit.</description>
        </group>
        <group group_id="E3">
          <title>No OptiVol Measurement</title>
          <description>All subjects either who were not followed for at least 6 months, or didn't have OptiVol Fluid Index measurements available.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="486"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="486"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Chest pressure/tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dyspnea/Shortness of breath</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E2" events="29" subjects_affected="21" subjects_at_risk="486"/>
                <counts group_id="E3" events="21" subjects_affected="18" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Fatigue, tiredness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Heart failure decompensation</sub_title>
                <counts group_id="E1" events="35" subjects_affected="24" subjects_at_risk="157"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="486"/>
                <counts group_id="E3" events="30" subjects_affected="24" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ischemic heart disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Near (pre) syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>PVC's</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Paroxysymal nocturnal dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Shoulder pain/discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="157"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Worsening cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>xOther Intrinsic Rhythm/Conduction Codes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>yOther patient disease/condition codes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>zAll &quot;Other&quot; codes</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="157"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="486"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Vascular heart disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="172" subjects_at_risk="486"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Arm/hand swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="486"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Chest pressure/tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="486"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dyspnea/Shortness of breath</sub_title>
                <counts group_id="E1" events="30" subjects_affected="23" subjects_at_risk="157"/>
                <counts group_id="E2" events="43" subjects_affected="39" subjects_at_risk="486"/>
                <counts group_id="E3" events="23" subjects_affected="19" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Fatigue, tiredness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Heart failure decompensation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="486"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Near (pre) syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>PVC's</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Paroxysymal nocturnal dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="486"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="486"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>xOther Intrinsic Rhythm/Conduction Codes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>yOther Patient Disease/Conduction Codes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="486"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>zAll &quot;Other&quot; Codes</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="486"/>
                <counts group_id="E3" events="17" subjects_affected="12" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In most cases, contracts allow investigators (&quot;PI&quot;) to publish per the publication strategy/Clinical Investigation Plan following Medtronic's review for (a) disclosure of confidential information (&quot;CI&quot;), and (b) selection and order of publications by the publications committee. Any such CI is deleted prior to publication/presentation. Medtronic may not otherwise censor/interfere with the publication. PI's may not publish single-site data until the main multi-site publication has occurred.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>CRDM Core Clinical</name_or_title>
      <organization>Medtronic CRDM Clinical Research</organization>
      <phone>800-328-2518</phone>
      <email>medtroniccrmtrials@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

